MUMBAI:
Roche
has launched a spinal muscular atrophy (SMA) treatment drug in India priced at around Rs 6 lakh per bottle. The drug, Evrysdi (risdiplam) is approved for the treatment of
SMA
in adults and children 2 months of age and older, Roche said, adding that it was approved by the Indian health authorities after reviewing its efficacy and safety data from three global clinical studies designed to represent a broad spectrum of people living with SMA.
Evrysdi was first approved by the
US FDA
in August 2020.
SMA is a severe, progressive rare neuromuscular disease that can be fatal. It affects approximately one in 10,000 live births globally and one in 7744 live births in India, and is the leading genetic cause of infant mortality, the company said.
V Simpson Emmanuel, CEO and
Managing Director
,
Roche Pharma India
says, “Today heralds a new journey of hope as we are all coming together to add color into the lives of SMA patients in India with the launch of Evrysdi, the first and only approved treatment in India for patients living with SMA. This also marks our foray into rare disease treatment in India”.
To further drive broader access to SMA patients in the country, Roche has announced a patient support programme for the drug.
Stay ahead in business with The Times of India. Check out Financial Calculators like SIP, PPF, FD, NPS and Mutual Fund Calculators.A business journalist with around two decades of experience track...
Read MoreA business journalist with around two decades of experience tracking key consumer-focussed sectors like consumer durables, retail, consumer goods, aviation, automobiles and advertising, as well as economic ministries of the Union government. Now, writes primarily on pharmaceuticals and healthcare, and on issues of consumer interest. Besides also looks at trends that are shaping consumer behaviour and the broad consumer landscape. \nYou can follow Rupali on Twitter@Rupalijee.
Read Less
Start a Conversation
Post comment